Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276620 | 0.83 | — | — | |
| SCHEMBL4551488 | 0.82 | TRIM24 (0.52) | CA1CA9ALDH1A1TRIM24TRIM33 | |
| SCHEMBL10364956 | 0.77 | CA1 (0.48) | CA1CA9ALDH1A1TRIM24TRIM33 | |
| SCHEMBL28461740 | 0.77 | CA1 (0.48) | CA1CA9ALDH1A1TRIM24TRIM33 | |
| SCHEMBL1999862 | 0.77 | CA1 (0.76) | CA1CA9ALDH1A1TRIM24TRIM33 | |
| SCHEMBL24567357 | 0.77 | CA1 (0.78) | CA1CA9ALDH1A1TRIM24TRIM33 | |
| SCHEMBL7060518 | 0.77 | CA1 (0.78) | CA1CA9ALDH1A1TRIM24TRIM33 | |
| SCHEMBL291354 | 0.77 | CA1 (0.78) | CA1CA9ALDH1A1TRIM24TRIM33 | |
| SCHEMBL7059546 | 0.77 | CA1 (0.78) | CA1CA9ALDH1A1TRIM24TRIM33 | |
| SCHEMBL7059169 | 0.77 | CA1 (0.78) | CA1CA9ALDH1A1TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298160-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| EP-4021916-A1 | 4'-ETHYNYL-2'-DEOXYADENOSINE DERIVATIVES AND THEIR USE IN HIV THERAPY | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2022-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298160-A1 | COMPOUNDS USEFUL IN HIV THERAPY | CCR5, CD4, LSS | CA1 4729/4885CA9 3529/4885ALDH1A1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.